The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder

Código QR

The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder

Zhida Bian,1,2,&ast; Hui Li,3,4,&ast; Yanlong Liu,5,&ast; Yanjun Cao,2 Yanxia Kang,2 Yongjun Yu,2 Feng Zhang,1,2 Cunbao Li,1 Yimin Kang,1 Fan Wang2,4 1Psychosomatic Medicine Research Division, Inner Mongolia Medical University, Huhhot, 010110, People’s Republic of China; 2Beijing Hui-Lon...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bian Z, Li H, Liu Y, Cao Y, Kang Y, Yu Y, Zhang F, Li C, Wang F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	major depressive disorder modified electroconvulsive therapy hypoxia-inducible factor neuroinflammation oxidative stress Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9aa01d715d594261840aa6469acc5f02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Electroconvulsive therapy in 77-year-old patient with pacemaker: a case report
por: Mędrala T, et al.
Publicado: (2018)

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): study protocol for a randomized non-inferiority trial of magnetic seizure therapy versus electroconvulsive therapy
por: Zafiris J. Daskalakis, et al.
Publicado: (2021)

Evaluation of cognitive impairment in patients with major depressive disorder in remission
por: Mustafa Ali, et al.
Publicado: (2021)

Reduced Synaptic Plasticity Contributes to Resistance Against Constant-Stimulus Electroconvulsive Treatment in a Rat Model of Stress-Induced Depression
por: Wu B, et al.
Publicado: (2021)

Severity of Depressive Symptoms is Associated with Venous Thromboembolism in Hospitalized Patients with a Major Depressive Episode
por: Yoshizawa K, et al.
Publicado: (2021)

Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016)

Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression
por: Zincir S, et al.
Publicado: (2016)

Predictors of Major Depressive Disorder in Older People
por: Susana Sousa, et al.
Publicado: (2021)

Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
por: Inoue T, et al.
Publicado: (2020)

BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study
por: Huang XB, et al.
Publicado: (2020)

Plasma complement component 4 increases in patients with major depressive disorder
por: Wei J, et al.
Publicado: (2017)

Atrophic Corpus Callosum Associated with Altered Functional Asymmetry in Major Depressive Disorder
por: Ran S, et al.
Publicado: (2020)

Electroconvulsive Therapy as a Corrector for Certain Side Effects of Antipsychotic Therapy
por: Yu. V. Bykov, et al.
Publicado: (2020)

Associations Between Tenascin-C and Testosterone Deficiency in Men with Major Depressive Disorder: A Cross-Sectional Retrospective Study
por: Peng R, et al.
Publicado: (2021)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang Q, et al.
Publicado: (2016)

Renoprotective Role of Hypoxia-Inducible Factors and the Mechanism
por: Qiu-Yu Li, et al.
Publicado: (2021)

Potential Genetic Overlap Between Insomnia and Sleep Symptoms in Major Depressive Disorder: A Polygenic Risk Score Analysis
por: Lindsay M. Melhuish Beaupre, et al.
Publicado: (2021)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
por: Roulot M, et al.
Publicado: (2018)

The role of neuroinflammation and neurovascular dysfunction in major depressive disorder
por: Jeon SW, et al.
Publicado: (2018)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada E, et al.
Publicado: (2016)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura R, et al.
Publicado: (2017)

Co-loading antioxidant N-acetylcysteine attenuates cytotoxicity of iron oxide nanoparticles in hypoxia/reoxygenation cardiomyocytes
por: Shen Y, et al.
Publicado: (2019)

Childhood Emotional Neglect Is Associated With Low Social Support in Chinese Patients With Major Depressive Disorder
por: Xuemei Qin, et al.
Publicado: (2021)

Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
por: F Kheirkhah, et al.
Publicado: (2010)

Elevated peripheral blood glutamate levels in major depressive disorder
por: Inoshita M, et al.
Publicado: (2018)

Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment
por: Xue-Qin Wang, et al.
Publicado: (2021)

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder
por: Chen S, et al.
Publicado: (2021)

Identifying factors associated with the hospital readmission rate among patients with major depressive disorder
por: Sharareh Parami, et al.
Publicado: (2021)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
por: Harada E, et al.
Publicado: (2017)

Disrupted Brain Entropy And Functional Connectivity Patterns Of Thalamic Subregions In Major Depressive Disorder
por: Xue SW, et al.
Publicado: (2019)

Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
por: Naghmeh Nikkheslat
Publicado: (2021)

Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data
por: Solem CT, et al.
Publicado: (2016)

Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder
por: Bo Q, et al.
Publicado: (2019)

The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder
por: Wang M, et al.
Publicado: (2019)

The Association Between Concentrations of Arginine, Ornithine, Citrulline and Major Depressive Disorder: A Meta-Analysis
por: Mingyue Fan, et al.
Publicado: (2021)

Serum Exosome-Derived miR-139-5p as a Potential Biomarker for Major Depressive Disorder
por: Liang JQ, et al.
Publicado: (2020)

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
por: Wang Y, et al.
Publicado: (2021)

Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases
por: Fuquan Zhang, et al.
Publicado: (2021)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
por: Hammer-Helmich L, et al.
Publicado: (2018)